ATE309795T1 - Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes - Google Patents

Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes

Info

Publication number
ATE309795T1
ATE309795T1 AT96943443T AT96943443T ATE309795T1 AT E309795 T1 ATE309795 T1 AT E309795T1 AT 96943443 T AT96943443 T AT 96943443T AT 96943443 T AT96943443 T AT 96943443T AT E309795 T1 ATE309795 T1 AT E309795T1
Authority
AT
Austria
Prior art keywords
pct
diagnosis
treatment
during sleep
acetylcholinesterase inhibitors
Prior art date
Application number
AT96943443T
Other languages
English (en)
Inventor
Jan Hedner
Original Assignee
Curapath Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curapath Ab filed Critical Curapath Ab
Application granted granted Critical
Publication of ATE309795T1 publication Critical patent/ATE309795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Radiation-Therapy Devices (AREA)
AT96943443T 1995-12-19 1996-12-17 Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes ATE309795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9504537A SE9504537D0 (sv) 1995-12-19 1995-12-19 Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
PCT/SE1996/001677 WO1997022339A1 (en) 1995-12-19 1996-12-17 Method of treating and diagnosing sleep disordered breathing and means for carrying out the method

Publications (1)

Publication Number Publication Date
ATE309795T1 true ATE309795T1 (de) 2005-12-15

Family

ID=20400641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96943443T ATE309795T1 (de) 1995-12-19 1996-12-17 Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes

Country Status (11)

Country Link
US (1) US6034117A (de)
EP (1) EP0923370B1 (de)
JP (1) JP3756193B2 (de)
AT (1) ATE309795T1 (de)
AU (1) AU701911B2 (de)
CA (1) CA2240717C (de)
DE (1) DE69635459T2 (de)
DK (1) DK0923370T3 (de)
ES (1) ES2256865T3 (de)
SE (1) SE9504537D0 (de)
WO (1) WO1997022339A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1030667E (pt) 1997-11-14 2005-06-30 Akzo Nobel Nv Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
US6352715B1 (en) * 1998-02-19 2002-03-05 Sagittarius Life Science Corp Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
ES2211215T3 (es) * 1998-12-24 2004-07-01 Janssen Pharmaceutica N.V. Composicion de galantamina de liberacion controlada.
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
US20070173893A1 (en) * 2000-10-20 2007-07-26 Pitts Walter C Method and apparatus for preventing obstructive sleep apnea
FR2820423B1 (fr) * 2001-02-05 2005-12-02 Assist Publ Hopitaux De Paris Tartrate et phosphate de 3,4-diaminopyridine, compositions pharmaceutiques et utilisations
CN1194688C (zh) * 2001-07-03 2005-03-30 山东绿叶制药股份有限公司 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
WO2004041281A1 (en) * 2002-11-01 2004-05-21 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US20040266659A1 (en) * 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
CA2535613A1 (en) 2003-08-13 2005-02-24 Janssen Pharmaceutica, N.V. Treatment of sleep disorders with cholinesterase inhibitors
EP1689704A2 (de) 2003-10-21 2006-08-16 CoLucid Pharmaceuticals, Inc. Carbamoylester, die cholinesterase inhibieren und pharmakologisch wirksame mittel freisetzen
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
US7984714B2 (en) * 2006-09-29 2011-07-26 Nellcor Puritan Bennett Llc Managing obstructive sleep apnea and/or snoring using local time released agents
EP2125709A2 (de) 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Verbindungen zur hemmung von cholinesterase
EP2182938A2 (de) * 2007-07-18 2010-05-12 Colucid Pharmaceuticals, Inc. Verfahren zur förderung der wachheit
EP2251010A1 (de) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Verwendungen von Thiabendazol und Derivaten davon zur Behandlung neurologischer Leiden
EP2672972B1 (de) * 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Verfahren zur behandlung von obstruktiver schlafapnoe
US9642841B1 (en) * 2014-03-14 2017-05-09 James M. Hand Snoring treatment
JP6526475B2 (ja) * 2015-04-30 2019-06-05 サンスター株式会社 経皮唾液腺投与用の唾液分泌促進剤
WO2017194551A1 (en) 2016-05-11 2017-11-16 Jan Hedner Sultiame for the treatment of sleep apnea

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
DE4115558A1 (de) * 1991-05-13 1992-11-19 Dresden Arzneimittel Prophylaktisches antidot gegen phosphororganische gifte
ATE183084T1 (de) * 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation

Also Published As

Publication number Publication date
DK0923370T3 (da) 2006-03-27
WO1997022339A1 (en) 1997-06-26
SE9504537D0 (sv) 1995-12-19
DE69635459T2 (de) 2006-08-03
CA2240717A1 (en) 1997-06-26
DE69635459D1 (de) 2005-12-22
AU1217697A (en) 1997-07-14
CA2240717C (en) 2002-11-26
ES2256865T3 (es) 2006-07-16
US6034117A (en) 2000-03-07
AU701911B2 (en) 1999-02-11
EP0923370A2 (de) 1999-06-23
EP0923370B1 (de) 2005-11-16
JP3756193B2 (ja) 2006-03-15
JP2000511873A (ja) 2000-09-12

Similar Documents

Publication Publication Date Title
ATE309795T1 (de) Acetylcholinesteraseinhibitoren zur behandlung und diagnose von atemstörungen während des schlafes
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69329559T2 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ZA953469B (en) New compound
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE59401401D1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
IL128877A0 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69636393D1 (de) Montirelin zur verhinderung der schlafapnoe
DE69634487D1 (de) Verfahren zur behandlung navikularer krankheiten bei pferden
DE69924146D1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
DE69525631T2 (de) Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
DE60118363D1 (de) Methoden zur behandlung des kryptorchysmus

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification

Ref document number: 0923370

Country of ref document: EP

REN Ceased due to non-payment of the annual fee